CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments
Chimeric antigen receptor (CAR)-T cell therapy is a progressive new pillar in immune cell
therapy for cancer. It has yielded remarkable clinical responses in patients with B-cell …
therapy for cancer. It has yielded remarkable clinical responses in patients with B-cell …
Chimeric antigen receptor T-cell therapies for lymphoma
JN Brudno, JN Kochenderfer - Nature reviews Clinical oncology, 2018 - nature.com
New therapies are needed for patients with Hodgkin or non-Hodgkin lymphomas that are
resistant to standard therapies. Indeed, unresponsiveness to standard chemotherapy and …
resistant to standard therapies. Indeed, unresponsiveness to standard chemotherapy and …
Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse
RM Shapiro, GC Birch, G Hu… - The Journal of …, 2022 - Am Soc Clin Investig
Background Responses to conventional donor lymphocyte infusion for postallogeneic
hematopoietic cell transplantation (HCT) relapse are typically poor. Natural killer (NK) cell …
hematopoietic cell transplantation (HCT) relapse are typically poor. Natural killer (NK) cell …
Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell …
JN Brudno, RPT Somerville, V Shi, JJ Rose… - Journal of clinical …, 2016 - ascopubs.org
Purpose Progressive malignancy is the leading cause of death after allogeneic
hematopoietic stem-cell transplantation (alloHSCT). After alloHSCT, B-cell malignancies …
hematopoietic stem-cell transplantation (alloHSCT). After alloHSCT, B-cell malignancies …
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study
Autologous T cells expressing a CD19-specific chimeric antigen receptor (CD19. CAR) are
active against B-cell malignancies, but it is unknown whether allogeneic CD19. CAR T cells …
active against B-cell malignancies, but it is unknown whether allogeneic CD19. CAR T cells …
[HTML][HTML] The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
Z Zhao, Y Chen, NM Francisco, Y Zhang… - Acta Pharmaceutica Sinica …, 2018 - Elsevier
Chimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy
where T lymphocytes are engineered with synthetic receptors known as chimeric antigen …
where T lymphocytes are engineered with synthetic receptors known as chimeric antigen …
Allogeneic CAR-T cells: more than ease of access?
C Graham, A Jozwik, A Pepper, R Benjamin - Cells, 2018 - mdpi.com
Patient derived anti-CD19 chimeric antigen receptor-T (CAR-T) cells are a powerful tool in
achieving a complete remission in a range of B-cell malignancies, most notably B-acute …
achieving a complete remission in a range of B-cell malignancies, most notably B-acute …
Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment
F Kreidieh, I Abou Dalle, N Moukalled… - International Journal of …, 2022 - Springer
Despite therapeutic progress in acute myeloid leukemia (AML), relapse post-allogeneic
hematopoietic stem cell transplantation (allo-HSCT) remains a major challenge. Here, we …
hematopoietic stem cell transplantation (allo-HSCT) remains a major challenge. Here, we …
CAR T cell therapy for chronic lymphocytic leukemia: successes and shortcomings
Z Todorovic, D Todorovic, V Markovic, N Ladjevac… - Current …, 2022 - mdpi.com
Chimeric antigen receptor T (CAR T) cell therapy achieved remarkable success in B-cell
leukemia and lymphoma which led to its incorporation in treatment protocols for these …
leukemia and lymphoma which led to its incorporation in treatment protocols for these …
Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies
K Shankar, CM Capitini, K Saha - Stem cell research & therapy, 2020 - Springer
Natural killer (NK) cells play a crucial role in host immunity by detecting cells that
downregulate MHC class I presentation and upregulate stress ligands, as commonly seen in …
downregulate MHC class I presentation and upregulate stress ligands, as commonly seen in …